Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(teriflunomide)
461 results
  • Mom Controls the Thermostat: Mitochondria Influence the Neuronal Firing Set Point. [Journal Article]
    Epilepsy Curr 2019; :1535759719868181Gallagher MJ
  • Mitochondrial Regulation of the Hippocampal Firing Rate Set Point and Seizure Susceptibility Styr B, Gonen N, Zarhin D, Ruggiero A, Atsmon R, Gazit N, Braun G, Frere S, Vertkin I, Shapira I, Harel M, Heim LR, Katsenelson M, Rechnitz O, Fadila S, Derdikman D, Rubinstein M, Geiger T, Ruppin E, Slutsky I. Neuron. 2019. pii: S0896-6273(19)30334-4. doi:10.1016/j.neuron.2019.03.045. [Epub ahead of prin…
  • Risk of cancer among Finnish multiple sclerosis patients. [Journal Article]
    Mult Scler Relat Disord 2019; 35:221-227Hongell K, Kurki S, … Soilu-Hänninen M
  • CONCLUSIONS: Overall risk of cancer in our MS cohort did not significantly differ from the controls. However, the age at diagnosis of breast cancer was statistically significantly higher among the MS patients in comparison with a control population from the same patient pool. Further population-based larger studies spanning longer follow-up periods and longer exposure to emerging MS therapies are needed to evaluate cancer risk related to MS treatments and breast cancer risk in particular.
  • Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers. [Journal Article]
    Clin Pharmacol Drug Dev 2019Rouini MR, Dibaei M, Ghasemian E
  • Multiple sclerosis, which is characterized by inflammation and neurodegeneration, is considered a chronic disease of the central nervous system. Given the lack of pharmacokinetic evaluation of teriflunomide in the Iranian context, the present 2-way crossover study aimed to assess the pharmacokinetic properties and bioequivalence of 2 teriflunomide formulations. To this end, 2 single-dose generic …
  • Immunological Aspects of Approved MS Therapeutics. [Review]
    Front Immunol 2019; 10:1564Rommer PS, Milo R, … Stuve O
  • Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape…
  • Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2. [Journal Article]
    Acta Pharmacol Sin 2019Liao XY, Deng QQ, … Pan GY
  • Rheumatoid arthritis patients can be prescribed a combination of immunosuppressive drug leflunomide (LEF) and the antiviral drug acyclovir to reduce the high risk of infection. Acyclovir is a substrate of organic anion transporter (OAT) 1/3 and multidrug resistance-associated protein (MRP) 2. Considering the extraordinarily long half-life of LEF's active metabolite teriflunomide (TER) and the kid…
New Search Next